TGFB1 and fibrosis: The results demonstrate that the blockade of TGF-β1/SMAD signaling with the new generation TGF-β1 receptor (TGF-β1R) antagonist, GW788388, dramatically inhibited the cardiac fibrosis and dysfunction in Npr1 mutant animals.